|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 4. Reduced epithelial proliferation in
Dgat1–/– mammary glands during pregnancy. (A)
Bromodeoxyuridine (BrdU) immunostaining. Pregnant (P15) mice were injected
with BrdU 2 hours before mammary glands were removed. Tissues were fixed,
embedded and sectioned, and proliferating nuclei were detected by BrdU
immunostaining (dark brown staining). (B) Quantification of BrdU-positive
nuclei. Epithelial areas were calculated using images of histological sections
(see Materials and methods), and positive nuclei from five random fields were
counted and expressed per unit of area (*P<0.05,
n=4 mice per genotype). The expression of BrdU-positive nuclei as a
percentage of total epithelial nuclei showed a similar reduction in
proliferating nuclei (9.76±1.02% for
Dgat1–/– versus 17.82±0.3% for wild
type, P=0.002, n=3). (C) Similar levels of apoptosis were
seen in mammary glands of wild-type and
Dgat1–/– mice at P18. Apoptotic epithelial
cells were detected by TUNEL staining and were counted in 10 random fields.
n=5 mice per genotype.
|
